Multiple tumor-associated antigens presented by autologous dendritic cells (DC vaccine)

Multiple tumor-associated antigens presented by autologous dendritic cells refers to a personalized cancer immunotherapy platform rather than a single molecular target. In this approach, a patient's own dendritic cells (DCs) are extracted and engineered to present a variety of tumor-specific or tumor-associated antigens (TAAs) to the immune system (NCI, 2023). By presenting multiple antigens simultaneously, the vaccine aims to elicit a broad immune response that reduces the likelihood of tumor escape through antigen loss (Banchereau & Palucka, 2005). This modality leverages the natural role of DCs as professional antigen-presenting cells to bridge innate and adaptive immunity, specifically priming CD8+ cytotoxic T cells to recognize and kill malignant cells (Galluzzi et al., 2014). Clinical applications include the treatment of solid tumors like glioblastoma and prostate cancer, where products like Sipuleucel-T and DCVax-L have demonstrated the potential to extend survival (Kantoff et al., 2010; Liau et al., 2023). Despite its promise, the field faces challenges related to the labor-intensive manufacturing process and the need for combination strategies to overcome the immunosuppressive tumor microenvironment.

Other names

Autologous dendritic cell vaccineTAA-pulsed dendritic cell vaccinePolyvalent dendritic cell vaccineDC-based cancer vaccineDendritic cell-based immunotherapy

Autologous dendritic cells are harvested from a patient, matured, and loaded ex vivo with multiple tumor-associated antigens (TAAs) via peptides, tumor lysates, or mRNA. Upon re-administration, these DCs migrate to lymph nodes where they present the TAAs on MHC class I and II molecules to naive T cells, stimulating a polyclonal cytotoxic T lymphocyte (CTL) and helper T cell response against the tumor (Anguille et al., 2014; Constantino et al., 2017).